Shaw Christine 4
4 · GenMark Diagnostics, Inc. · Filed Dec 9, 2020
Insider Transaction Report
Form 4
Shaw Christine
VP, Assay Development
Transactions
- Sale
Common Stock
2020-12-07$13.97/sh−274$3,828→ 79,877 total
Footnotes (2)
- [F1]The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted restricted stock units.
- [F2]Includes 860 shares acquired under the GenMark Diagnostics, Inc. employee stock purchase plan, the reporting of which is exempt under both Rule 16b-3(d) and Rule 16b-3(c).